Evidence & Research Status
Not everyone with obesity responds the same way to tirzepatide, and a 2026 Mayo Clinic study published in Gastroenterology may help explain why. Researchers identified an obesity subtype defined by…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
Not everyone with obesity responds the same way to tirzepatide, and a 2026 Mayo Clinic study published in Gastroenterology may help explain why. Researchers identified an obesity subtype defined by fast gastric emptying, unexpectedly low post-meal GLP-1 levels, and heightened hunger after eating — and people fitting that profile lost nearly twice as much weight on tirzepatide as those with other obesity phenotypes.
What the Study Found
Researchers analyzed 483 adults with obesity, characterizing physiologic subtypes by measuring gastric emptying rate, appetite regulation, and post-meal levels of enteroendocrine hormones including GLP-1. They identified a distinct subphenotype, sometimes described informally as a “hungry gut” pattern, present in more than 1 in 4 participants: fast gastric emptying paired with discordantly low postprandial GLP-1 and increased post-meal hunger. In a retrospective analysis, participants with this subphenotype lost an average of 21.5% of body weight after six months of tirzepatide, compared with 11.7% for participants with other, “concordant” obesity phenotypes (source).
Why This Matters for Precision Obesity Research
Obesity is increasingly understood as a heterogeneous condition rather than a single uniform diagnosis. This study adds physiologic evidence to that view: people with the fast-gastric-emptying, low-GLP-1 subtype may be under-producing their own GLP-1 response to meals, which could explain why supplementing GLP-1/GIP receptor activity pharmacologically produces an outsized effect in that group specifically, rather than a uniform effect across everyone with obesity.
What This Study Does Not Show
This is preliminary, retrospective precision-medicine research, not a validated clinical test. It does not establish that routine GLP-1 or gastric-emptying testing can currently guide medication choice in practice, that every person with this subtype will respond as strongly, or that people without this subtype will not benefit from tirzepatide — the “concordant” group still lost substantial weight (11.7%) on average. Findings need replication in larger, more diverse, prospective populations before any testing-based treatment selection could be considered clinically validated.
Individual Response Varies — Averages Describe Groups, Not People
| Metric | “Hungry Gut” Subtype (~25%+ of participants) | Other Phenotypes |
|---|---|---|
| Gastric emptying | Fast | Typical/varied |
| Post-meal GLP-1 | Discordantly low | Higher |
| Post-meal hunger | Increased | Lower |
| Average weight loss at 6 months (tirzepatide) | 21.5% | 11.7% |
Open Questions for Researchers
- Can this subtype eventually be identified with a simple, clinically accessible test rather than research-grade gastric-emptying and hormone measurement?
- Does the same subtype predict differential response to other GLP-1/GIP/glucagon-receptor compounds, such as semaglutide or retatrutide?
- Do the two groups differ in durability of weight loss, discontinuation rates, or side-effect profile, not just magnitude of weight loss?
- How would a prospective, randomized study using subtype-based treatment assignment change these results?
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.